Evoke Pharma Total Liabilities 2012-2024 | EVOK
Evoke Pharma total liabilities from 2012 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Evoke Pharma Annual Total Liabilities
(Millions of US $) |
| 2023 |
$10 |
| 2022 |
$8 |
| 2021 |
$7 |
| 2020 |
$13 |
| 2019 |
$2 |
| 2018 |
$2 |
| 2017 |
$6 |
| 2016 |
$6 |
| 2015 |
$6 |
| 2014 |
$6 |
| 2013 |
$4 |
| 2012 |
$2 |
| 2011 |
$0 |
Evoke Pharma Quarterly Total Liabilities
(Millions of US $) |
| 2024-09-30 |
$10 |
| 2024-06-30 |
$9 |
| 2024-03-31 |
$9 |
| 2023-12-31 |
$10 |
| 2023-09-30 |
$9 |
| 2023-06-30 |
$8 |
| 2023-03-31 |
$8 |
| 2022-12-31 |
$8 |
| 2022-09-30 |
$8 |
| 2022-06-30 |
$7 |
| 2022-03-31 |
$7 |
| 2021-12-31 |
$7 |
| 2021-09-30 |
$7 |
| 2021-06-30 |
$12 |
| 2021-03-31 |
$11 |
| 2020-12-31 |
$13 |
| 2020-09-30 |
$9 |
| 2020-06-30 |
$9 |
| 2020-03-31 |
$2 |
| 2019-12-31 |
$2 |
| 2019-09-30 |
$2 |
| 2019-06-30 |
$1 |
| 2019-03-31 |
$1 |
| 2018-12-31 |
$2 |
| 2018-09-30 |
$2 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$6 |
| 2017-09-30 |
$9 |
| 2017-06-30 |
$6 |
| 2017-03-31 |
$7 |
| 2016-12-31 |
$6 |
| 2016-09-30 |
$6 |
| 2016-06-30 |
$6 |
| 2016-03-31 |
$6 |
| 2015-12-31 |
$6 |
| 2015-09-30 |
$6 |
| 2015-06-30 |
$6 |
| 2015-03-31 |
$6 |
| 2014-12-31 |
$6 |
| 2014-09-30 |
$2 |
| 2014-06-30 |
$2 |
| 2014-03-31 |
$4 |
| 2013-12-31 |
$4 |
| 2013-09-30 |
$5 |
| 2013-06-30 |
$4 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
|
| 2012-09-30 |
$0 |
| 2012-06-30 |
$0 |
| 2011-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.008B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
